Citigroup Initiates Coverage On Rhythm Pharmaceuticals with Buy Rating, Announces Price Target of $136

Benzinga · 11/25/2025 14:16
Citigroup analyst Samantha Semenkow initiates coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy rating and announces Price Target of $136.